BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ:OSUR), a market leader in oral fluid diagnostics, today announced that an evaluation by the Walter Reed Army Institute of Research of the OraQuick® HCV Test, currently in clinical development by OraSure Technologies, was recently released at the Advanced Technology Applications for Combat Casualty Care meeting, sponsored by the Department of Defense. The purpose of the evaluation, entitled “Laboratory Evaluation of Hepatitis C Rapid Test for Use in Screening Walking Blood Bank Donors,” was to determine the best rapid HCV test to use for screening blood donors for hepatitis C (“HCV”) in the theater of war. The OraQuick® HCV test was selected as the preferred test based on all facets of the evaluation.
